High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF study: Brief communication

American Journal of Transplantation

Volumn 10, Issue 7, 2010, Pages 1704-1709

  Martinez, F ^a   Kamar, N ^b   Pallet, N ^a   Lang, P ^c   Durrbach, A ^d   Lebranchu, Y ^e   Adem, A ^f   Barbier, S ^g   Cassuto Viguier, E ^h   Glowaki, F ⁱ   Le Meur, Y ^j   Rostaing, L ^b   Legendre, C ^a   Hermine, O ^a   Choukroun, G ^k  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CHU RANGUEIL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ DE TOURS   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^h PASTEUR HOSPITAL   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j BREST UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

more..

Author keywords

Delayed graft function; epoetin; ischemia reperfusion; renal transplantation

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLOGRAFT ARTERIAL THROMBOSIS; ARTERIOVENOUS FISTULA; ARTERY THROMBOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DELAYED GRAFT FUNCTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL TIME; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS;

EID: 77954078811     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03142.x     Document Type: Article

References (23)

1. Perico N, Cattaneo D, Sayegh M, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004 364 : 1814 1827.
2. Peeters P, Terryn W, Vanholder R, Lameire N. Delayed graft function in renal transplantation. Curr Opin Crit Care 2004 10 : 489 498.
3. Tapiawala S, Tinckam K, Cardella C et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol 2009 Nov 19 [Epub ahead of print].
4. Yarlagadda S, Coca S, Formica RJ, Poggio E, Parikh C. Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis. Nephrol Dial Transplant 2009 24 : 1039 1047.
5. Peeters P, Vanholder R. Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: Mission impossible? Transplantation 2008 15 : S31 S37.
6. Cariou A, Claessens Y, Pène F et al. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: A matched control study. Resuscitation 2008 76 : 397 404.
7. Edelstein CL, Shi Y, Schrier RW. Role of caspases in hypoxia-induced necrosis of rat renal proximal tubules. J Am Soc Nephrol 1999 10 : 1940 1949.
8. Pallet N, Bouvier N, Legendre C et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2009 Sep 18 [Epub ahead of print].
9. Lee SH, Li C, Lim SW et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005 25 : 64 76.
10. Salahudeen AK, Haider N, Jenkins J et al. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2008 294 : F1354 F1365.
11. Bohlius J, Schmidlin K, Brillant C. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009 373 : 1532 1542.
12. Singh A, Szczech L, Tang K et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 355 : 2085 2098.
13. Halloran P, Hunsicke RL. Delayed graft function: State of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001 1 : 115 120.
14. Hernández D, Rufino M, González-Posada J et al. Predicting delayed graft function and mortality in kidney transplantation. Transplant Rev (Orlando) 2008 22 : 21 26.
15. Kamar N, Garrigue V, Karras A et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: A randomized, multicenter study. Am J Transplant 2006 6 : 1042 1048.
16. Corwin H, Gettinger A, Pearl R et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002 288 : 2827 2835.
17. Sharples E, Patel N, Brown P, Stewart K. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004 15 : 2115 2124. (Pubitemid 39031350)
18. Locatelli F, Aljama P, Bárány P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004 19 (Suppl 2 ii1 47.
19. Stüben G, Pöttgen C, Knühmann K et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003 55 : 1358 1362.
20. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005 79 : 367 368.
21. Binbrek A, Rao N, Al Khaja N, Assaqqaf J, Sobel B. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009 104 : 1035 1040.
22. Pfeffer M, Burdmann E, Chen C, Cooper M. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009 361 : 2019 2032.
23. Newland A, Black C. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother 2008 42 : 1865 1870.